DE69833876T2 - Zusammensetzungen und verfahren für die gezielte abgabe von faktoren - Google Patents

Zusammensetzungen und verfahren für die gezielte abgabe von faktoren Download PDF

Info

Publication number
DE69833876T2
DE69833876T2 DE69833876T DE69833876T DE69833876T2 DE 69833876 T2 DE69833876 T2 DE 69833876T2 DE 69833876 T DE69833876 T DE 69833876T DE 69833876 T DE69833876 T DE 69833876T DE 69833876 T2 DE69833876 T2 DE 69833876T2
Authority
DE
Germany
Prior art keywords
cells
specific
cell
binding
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833876T
Other languages
German (de)
English (en)
Other versions
DE69833876D1 (de
Inventor
Lawrence Rockville TAMARKIN
F. Giulio Baltimore PACIOTTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytimmune Sciences Inc
Original Assignee
Cytimmune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/966,940 external-priority patent/US6274552B1/en
Application filed by Cytimmune Sciences Inc filed Critical Cytimmune Sciences Inc
Application granted granted Critical
Publication of DE69833876D1 publication Critical patent/DE69833876D1/de
Publication of DE69833876T2 publication Critical patent/DE69833876T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69833876T 1997-11-10 1998-11-10 Zusammensetzungen und verfahren für die gezielte abgabe von faktoren Expired - Lifetime DE69833876T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US08/966,940 US6274552B1 (en) 1993-03-18 1997-11-10 Composition and method for delivery of biologically-active factors
US7581198P 1998-02-24 1998-02-24
US75811P 1998-02-24
US8669698P 1998-05-26 1998-05-26
US86696P 1998-05-26
US10745598P 1998-11-06 1998-11-06
US107455P 1998-11-06
PCT/US1998/023931 WO1999024077A2 (en) 1997-11-10 1998-11-10 Compositions and methods for targeted delivery of biologically-active factors
US966940 2001-09-28

Publications (2)

Publication Number Publication Date
DE69833876D1 DE69833876D1 (de) 2006-05-11
DE69833876T2 true DE69833876T2 (de) 2007-05-24

Family

ID=27491221

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833876T Expired - Lifetime DE69833876T2 (de) 1997-11-10 1998-11-10 Zusammensetzungen und verfahren für die gezielte abgabe von faktoren

Country Status (9)

Country Link
US (1) US20090035265A1 (https=)
EP (1) EP1044022B1 (https=)
JP (1) JP4620243B2 (https=)
AT (1) ATE320270T1 (https=)
AU (1) AU760035B2 (https=)
CA (1) CA2309604C (https=)
DE (1) DE69833876T2 (https=)
NZ (1) NZ504291A (https=)
WO (1) WO1999024077A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
ATE317269T1 (de) * 1997-11-10 2006-02-15 Cytimmune Sciences Inc Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs)
JP2009286808A (ja) * 1997-11-10 2009-12-10 Cytimmune Sciences Inc 生物学的に活性な因子の標的化された送達のための組成物および方法
CA2448607C (en) * 2001-04-30 2013-01-22 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
AU2004311630A1 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US8877156B2 (en) 2007-06-26 2014-11-04 New York University Contrast agents anchored by thiols on nanoparticles
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
JP5265762B2 (ja) 2008-05-13 2013-08-14 ユニバーシティ・オブ・カンザス 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
US20250034221A1 (en) * 2023-07-25 2025-01-30 Zahav Bioscience Llc Cytokine compositions and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5047523A (en) * 1988-08-02 1991-09-10 Ortho Diagnostic Systems Inc. Nucleic acid probe for detection of neisseria gonorrhoea
US5248772A (en) * 1992-01-29 1993-09-28 Coulter Corporation Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents
EP0690722B1 (en) * 1993-03-18 2004-06-30 Cytimmune Sciences, Inc. Composition and method for reducing toxicity of biologically-active factors
JPH07227299A (ja) * 1994-02-14 1995-08-29 Kyoto Daiichi Kagaku:Kk Ｄｎａの特定塩基配列の検出方法及びその装置
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
EP0837696B1 (en) * 1995-06-07 2010-02-24 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
ES2210514T3 (es) * 1996-04-10 2004-07-01 Sangstat Medical Corporation Conjugados citomoduladores de miembros de pares de union especificos.
DE19622628A1 (de) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Stabilisierung von Metallkonjugaten
EP0960204A4 (en) * 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
ES2248898T3 (es) * 1997-05-02 2006-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Inmunotoxinas que comprenden una proteina onc dirigida contra celulas malignas.
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression

Also Published As

Publication number Publication date
CA2309604C (en) 2010-01-12
AU1394099A (en) 1999-05-31
EP1044022A2 (en) 2000-10-18
EP1044022B1 (en) 2006-03-15
WO1999024077A2 (en) 1999-05-20
US20090035265A1 (en) 2009-02-05
CA2309604A1 (en) 1999-05-20
WO1999024077A3 (en) 1999-10-07
ATE320270T1 (de) 2006-04-15
AU760035B2 (en) 2003-05-08
NZ504291A (en) 2002-10-25
JP4620243B2 (ja) 2011-01-26
DE69833876D1 (de) 2006-05-11
JP2001522818A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
US6274552B1 (en) Composition and method for delivery of biologically-active factors
DE69433870T2 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
DE69833876T2 (de) Zusammensetzungen und verfahren für die gezielte abgabe von faktoren
USRE42524E1 (en) Colloidal metal compositions and methods
US7790167B2 (en) Methods and compositions for enhancing immune response and for the production of in vitro Mabs
JP2009215319A (ja) コロイド状金属組成物および方法
US8137989B2 (en) Method for delivering a cytokine using a colloidal metal
US20050175584A1 (en) Functionalized colloidal metal compositions and methods
DE69833455T2 (de) Verfahren und zusammensetzungen zur verstärkung der immunantwort und zur in-vitro herstellung von monoklonalen antikörpern (mabs)
AU2003231660B2 (en) Compositions and methods for targeted delivery of factors
US20250235557A1 (en) Method of gene targeting utilizing outer membrane vesicle
JP2009286808A (ja) 生物学的に活性な因子の標的化された送達のための組成物および方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition